Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE) in human immunodeficiency virus type-1 seropositive subjects - PubMed (original) (raw)
Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE) in human immunodeficiency virus type-1 seropositive subjects
R B Moss et al. Viral Immunol. 1997.
Abstract
Lymphocyte proliferation responses to gp120-depleted HZ321 virus (clade A) antigen were compared to BAL human immunodeficiency virus (HIV) virus antigen (clade B) responses, clade E HIV virus antigen responses, and purified native p24 antigen responses in 15 human immunodeficiency virus type-1 (HIV-1) seropositive subjects immunized with a whole-killed inactivated gp120-depleted HIV-1 antigen in Incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE). A significant increase in lymphocyte proliferation to HZ321 antigen was observed after immunization with the HIV-1 immunogen (p = 0.02). A strong association was demonstrated between the HIV-1 immunizing antigen, HZ321, and native p24 antigen responses (r = 0.80, p < 0.0001). Furthermore, a strong association in terms of proliferative responses was demonstrated between HZ321 virus (clade A) responses and BAL virus (clade B) (r = 0.95, p < 0.0001) and clade E virus antigen (r = 0.92, p < 0.0001). Proliferative responses to HIV antigens also correlated with baseline CD4 counts. Taken together, these results support the specificity of immune responses induced by REMUNE (HIV-1 immunogen). The development of cross-reactive immune responses between clades and to the more conserved epitopes of the virus have implications in the development of therapeutic and prophylactic HIV vaccines.
Similar articles
- In vitro p24 antigen-stimulated lymphocyte proliferation and beta-chemokine production in human immunodeficiency virus type 1 (HIV-1)-seropositive subjects after immunization with an inactivated gp120-depleted HIV-1 immunogen (Remune).
Moss RB, Wallace MR, Lanza P, Giermakowska W, Jensen FC, Theofan G, Chamberlin C, Richieri SP, Carlo DJ. Moss RB, et al. Clin Diagn Lab Immunol. 1998 May;5(3):308-12. doi: 10.1128/CDLI.5.3.308-312.1998. Clin Diagn Lab Immunol. 1998. PMID: 9605982 Free PMC article. Clinical Trial. - Tumor necrosis factor alpha and human immunodeficiency virus-specific functional immune responses after immunization with Gp120-depleted, inactivated HIV-1 in incomplete Freund's adjuvant (REMUNE) in HIV-1-seropositive subjects.
Moss RB, Li L, Giermakowska WK, Lanza P, Turner JL, Wallace MR, Jensen FC, Richieri SP, Daigle AE, Theofan G, Carlo DJ. Moss RB, et al. J Hum Virol. 1998 Jan-Feb;1(2):77-81. J Hum Virol. 1998. PMID: 10195235 Clinical Trial. - Safety and immunogenicity of a gp120-depleted, inactivated HIV-1 immunogen: results of a double-blind, adjuvant controlled trial.
Trauger RJ, Daigle AE, Giermakowska W, Moss RB, Jensen F, Carlo DJ. Trauger RJ, et al. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 2:S74-82. J Acquir Immune Defic Syndr Hum Retrovirol. 1995. PMID: 7552517 Clinical Trial. - Inactivated HIV-1 Immunogen: impact on markers of disease progression.
Moss RB, Ferré F, Trauger R, Jensen F, Daigle A, Richieri SP, Carlo DJ. Moss RB, et al. J Acquir Immune Defic Syndr (1988). 1994;7 Suppl 1:S21-7. J Acquir Immune Defic Syndr (1988). 1994. PMID: 7910207 Review. - Biological consequences of human immunodeficiency virus type 1 envelope polymorphism: does variation matter? 1995 Fleming Lecture.
McKeating JA. McKeating JA. J Gen Virol. 1996 Dec;77 ( Pt 12):2905-19. doi: 10.1099/0022-1317-77-12-2905. J Gen Virol. 1996. PMID: 9000081 Review. No abstract available.
Cited by
- Viral inactivation by light.
Sadraeian M, Zhang L, Aavani F, Biazar E, Jin D. Sadraeian M, et al. eLight. 2022;2(1):18. doi: 10.1186/s43593-022-00029-9. Epub 2022 Sep 26. eLight. 2022. PMID: 36187558 Free PMC article. Review. - Application of radiation technology in vaccines development.
Seo HS. Seo HS. Clin Exp Vaccine Res. 2015 Jul;4(2):145-58. doi: 10.7774/cevr.2015.4.2.145. Epub 2015 Jul 29. Clin Exp Vaccine Res. 2015. PMID: 26273573 Free PMC article. Review. - Effects of adjuvants for human use in systemic lupus erythematosus (SLE)-prone (New Zealand black/New Zealand white) F1 mice.
Favoino E, Favia EI, Digiglio L, Racanelli V, Shoenfeld Y, Perosa F. Favoino E, et al. Clin Exp Immunol. 2014 Jan;175(1):32-40. doi: 10.1111/cei.12208. Clin Exp Immunol. 2014. PMID: 24112107 Free PMC article. - Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus.
Chertova E, Bess JW Jr, Crise BJ, Sowder II RC, Schaden TM, Hilburn JM, Hoxie JA, Benveniste RE, Lifson JD, Henderson LE, Arthur LO. Chertova E, et al. J Virol. 2002 Jun;76(11):5315-25. doi: 10.1128/jvi.76.11.5315-5325.2002. J Virol. 2002. PMID: 11991960 Free PMC article. - A double-blind, adjuvant-controlled trial of human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) monotherapy in asymptomatic, HIV-1-infected thai subjects with CD4-cell counts of >300.
Churdboonchart V, Sakondhavat C, Kulpradist S, Na Ayudthya BI, Chandeying V, Rugpao S, Boonshuyar C, Sukeepaisarncharoen W, Sirawaraporn W, Carlo DJ, Moss R. Churdboonchart V, et al. Clin Diagn Lab Immunol. 2000 Sep;7(5):728-33. doi: 10.1128/CDLI.7.5.728-733.2000. Clin Diagn Lab Immunol. 2000. PMID: 10973445 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials